Drug Resistance, Multiple, Bacterial
4
2
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Microbiome Testing Duodenal Aspirate
Research Leaders
5 sponsors active, led by Marco J. Bruno
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
Aztreonam-Avibactam in Immunocompromised Hosts
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries
Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU
Research Network
Common Treatments
- Microbiome Testing Duodenal Aspirate1
- Mdrotesting Duodenal Aspirate1
- Multidrugresistant Organisms Mdro Testing Through Rectal And Oralnasal Swabs1
- Microbiome Through Rectal Swab1
- Ceftazidimeavibactam Plus Aztreonam1
Active Sponsors
- Marco J. Bruno1
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno1
- Boston Scientific Corporation1
- Tourcoing Hospital1
- Centre Hospitalier Régional d'Orléans1
Top Investigators
Centre Hospitalier Universitaire d'Orléans
Erasmus Medical Center
CEMIC - Centro de Educación Médica e Investigaciones Clínicas "Dr. Norberto Quirno"
CEMIC - Centro de Educación Médica e Investigaciones Clínicas "Dr. Norberto Quirno"
CEMIC - Centro de Educación Médica e Investigaciones Clínicas "Dr. Norberto Quirno"
Related Conditions
- Carbapenemresistant Enterobacteriaceae Infection1
- Antibacterial Agents1
- Betalactam Antibiotics1
- Enterobacteriaceae Infections1
- Immunocompromised Host1